Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab

We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.

Detalles Bibliográficos
Autores principales: de Brito, Marianne, Huebner, Gisela, Murrell, DedeeF, Bullpitt, Peter, Hartmann, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149008/
https://www.ncbi.nlm.nih.gov/pubmed/30258566
http://dx.doi.org/10.1186/s13601-018-0222-y
_version_ 1783356800049872896
author de Brito, Marianne
Huebner, Gisela
Murrell, DedeeF
Bullpitt, Peter
Hartmann, Karin
author_facet de Brito, Marianne
Huebner, Gisela
Murrell, DedeeF
Bullpitt, Peter
Hartmann, Karin
author_sort de Brito, Marianne
collection PubMed
description We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.
format Online
Article
Text
id pubmed-6149008
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61490082018-09-26 Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab de Brito, Marianne Huebner, Gisela Murrell, DedeeF Bullpitt, Peter Hartmann, Karin Clin Transl Allergy Letter to the Editor We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis. BioMed Central 2018-09-21 /pmc/articles/PMC6149008/ /pubmed/30258566 http://dx.doi.org/10.1186/s13601-018-0222-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
de Brito, Marianne
Huebner, Gisela
Murrell, DedeeF
Bullpitt, Peter
Hartmann, Karin
Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
title Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
title_full Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
title_fullStr Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
title_full_unstemmed Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
title_short Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
title_sort normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149008/
https://www.ncbi.nlm.nih.gov/pubmed/30258566
http://dx.doi.org/10.1186/s13601-018-0222-y
work_keys_str_mv AT debritomarianne normocomplementaemicurticarialvasculitiseffectivetreatmentwithomalizumab
AT huebnergisela normocomplementaemicurticarialvasculitiseffectivetreatmentwithomalizumab
AT murrelldedeef normocomplementaemicurticarialvasculitiseffectivetreatmentwithomalizumab
AT bullpittpeter normocomplementaemicurticarialvasculitiseffectivetreatmentwithomalizumab
AT hartmannkarin normocomplementaemicurticarialvasculitiseffectivetreatmentwithomalizumab

Ejemplares similares